Rectal Cancer
Reports Outline Rectal Cancer Study Results from G. Gasparini et al
Published in Drug Week, March 23rd, 2012
2012 MAR 23 -- In this recently published article, scientists in Milan, Italy conducted a study "To assess safety and activity of neoadjuvant bevacizumab, capecitabine and standard radiotherapy in locally advanced rectal cancer as well as potential predictive biomarkers. The multicentric phase II study enrolled 43 patients who received bevacizumab infusion (5 mg/kg) every 2 weeks for 4 cycles; oral capecitabine at 825 mg/m(2) twice a day for 5.5 weeks with external-beam irradiation (50.4 Gy in 28 fractions over 5.5 weeks)."
"We determined certain biomarkers before and after therapy for correlation with response. Post-operative histologic examination...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2012-03-23)
More Articles from Drug Week
- Pseudomonas
Yantai Institute of Coastal Zone Research Publishes Research in Pseudomonas - Glioblastomas
Yale University Reports Research in Glioblastomas - Cell Surface Receptors
Yale University Publishes Research in Cell Surface Receptors - Alcohol Oxidoreductases
Wenzhou Medical College Details Research in Alcohol Oxidoreductases - Antibiotics
Xinyang Normal University Details Research in Antibiotics - Weight Loss
Wellspring at Structure House Announces New Executive Director, Thomas Britton - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
